Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury

Intensive Care Medicine Experimental

Volumn 7, Issue , 2019, Pages

  Juschten, Jenny ^a,b   Ingelse, Sarah Anne ^b,c   Maas, Martinus Adrianus Wilhelmus ^b   Girbes, Armand Roelof Johan ^a   Juffermans, Nicole Petra ^b   Schultz, Marcus Josephus ^b,d   Tuinman, Pieter Roel ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute lung injury; Alpha 1 protease inhibitor; Antithrombin; ARDS; Coagulation; Inflammation; Lung injury model

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN CONCENTRATE; ANTITHROMBIN; ANTITHROMBIN III; BUPRENORPHINE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING; BLOOD GAS ANALYSIS; BREATHING RATE; CAROTID ARTERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FIBRINOLYSIS; IMMUNE RESPONSE; INFLAMMATION; LACTIC ACIDOSIS; MALE; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; TIDAL VOLUME; TRACHEOTOMY;

EID: 85072866266     PISSN: None     EISSN: 2197425X     Source Type: Journal    
DOI: 10.1186/s40635-019-0240-7     Document Type: Article

References (36)

1. Matthay MA, Zemans RL (2011) The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 6:147–163
2. Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ (2012) Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations. Crit Care 16(2):R70
3. Afshari A, Wetterslev J, Brok J, Moller AM (2008) Antithrombin III for critically ill patients. Cochrane Database Syst Rev 3 CD005370
4. Ware LB, Fang X, Matthay MA (2003) Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285(3):L514–L521
5. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD et al (2007) Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 35(8):1821–1828
6. Chambers RC, Scotton CJ (2012) Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc 9(3):96–101
7. Ehlers MR (2014) Immune-modulating effects of alpha-1 antitrypsin. Biol Chem 395(10):1187–1193
8. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T (2011) The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med 105(8):1129–1139
9. KA B. Antithrombin deficiency UpToDate2016 [updated April 28, 2016. Available from: www.uptodate.com/contents/antithrombin-deficiency?source=search_result&search=antithrombin&selectedTitle=1~150
10. Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ (2003) Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 90(6):1150–1157
11. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H et al (2002) Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 99(11):4015–4020
12. Redens TB, Leach WJ, Bogdanoff DA, Emerson TE, Jr. Synergistic protection from lung damage by combining antithrombin-III and alpha 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. Circ Shock 1988;26(1):15–26
13. Cornet AD, Groeneveld AB, Hofstra JJ, Vlaar AP, Tuinman PR, van Lingen A et al (2014) Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. PLoS One 9(3):e90983
14. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, Girbes AR et al (2013) Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 11(5):894–901
15. Juschten J, Tuinman PR, Juffermans NP, Dixon B, Levi M, Schultz MJ (2017) Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies. Ann Transl Med 5(22):444
16. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review. Crit Care Med 34(3):871–877
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709
18. Aslami H, Haitsma JJ, Hofstra JJ, Florquin S, Dos Santos C, Streutker C et al (2012) Plasma-derived human antithrombin attenuates ventilator-induced coagulopathy but not inflammation in a Streptococcus pneumoniae pneumonia model in rats. J Thromb Haemost 10(3):399–410
19. Choi G, Vlaar AP, Schouten M, Van't Veer C, van der Poll T, Levi M et al (2007) Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 30(3):423–428
20. Gao W, Zhao J, Kim H, Xu S, Chen M, Bai X et al (2014) alpha1-antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death. J Heart Lung Transplant 33(3):309–315
21. Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ (2002) Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115(Pt 1):227–236
22. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K (1996) Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Phys 270(6 Pt 1):L921–L930
23. Grommes J, Soehnlein O (2011) Contribution of neutrophils to acute lung injury. Mol Med 17(3–4):293–307
24. Cochrane CG (1988) Alpha-1-proteinase inhibitor in inflammatory states of humans and laboratory animals. Am J Med 84(6A):75–79
25. Wallaert B, Aerts C, Gressier B, Gosset P, Voisin C (1993) Oxidative inactivation of alpha 1-proteinase inhibitor by alveolar epithelial type II cells. J Appl Physiol 75(6):2376–2382
26. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, van der Zee JS et al (2008) Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 36(1):204–210
27. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama 286(15):1869–1878
28. Subramaniyam D, Steele C, Kohnlein T, Welte T, Grip O, Matalon S et al (2010) Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo. Inflamm Res 59(7):571–578
29. Jonigk D, Al-Omari M, Maegel L, Muller M, Izykowski N, Hong J et al (2013) Anti-inflammatory and immunomodulatory properties of alpha1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 110(37):15007–15012
30. Pott GB, Beard KS, Bryan CL, Merrick DT, Shapiro L (2013) Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health 1:19
31. Matute-Bello G, Frevert CW, Martin TR (2008) Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 295(3):L379–L399
32. Rojas M, Woods CR, Mora AL, Xu J, Brigham KL (2005) Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. Am J Physiol Lung Cell Mol Physiol. 288(2):L333–L341
33. Tuinman PR, Muller MC, Jongsma G, Hegeman MA, Juffermans NP (2013) High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock 40(4):334–338
34. Yang CL, Chen CH, Tsai PS, Wang TY, Huang CJ (2011) Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. J Surg Res 167(2):e273–e281
35. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G et al (2010) Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 23(2):105–111
36. Uchiba M, Okajima K (1997) Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III. Semin Thromb Hemost 25(6):583–590